|29.56|| +0.04 / +0.14%|
PTC Therapeutics, Inc. is a biopharmaceutical company, which is focused on the discovery, development and commercialization of orally administered, small molecule therapeutics targeting an area of RNA biology. The company's preclinical and discovery programs are focused on the development of new treatments for multiple therapeutic areas, including neuromuscular disease, oncology and infectious disease. The company's lead product, candidate ataluren, is used for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. PTC Therapeutics was founded by Allan S. Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
|Stuart W. Peltz||Chief Executive Officer & Director|
|Neil Gregory Almstead||Executive VP-Research, Operations & Technology|
|Shane William Charles Kovacs||CFO & Head-Corporate Development|
|Robert Jay Spiegel||Chief Medical Officer|
|Mark Elliott Boulding||Secretary, Chief Legal Officer & Executive VP|